dear
editor
emerg
reemerg
virus
caus
respiratori
infecti
diseas
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
influenza
virus
signific
threat
public
health
worldwid
although
vaccin
effect
strategi
prevent
viral
infect
vaccin
develop
long
process
may
effect
correspond
viru
therefor
essenti
develop
antivir
agent
intranas
administr
nonspecif
prophylaxi
infect
emerg
reemerg
respiratori
virus
epidem
pandem
potenti
cholera
toxin
ct
act
mucos
adjuv
stimul
mucos
system
immun
respons
potenti
intranas
applic
immunotherapeut
infect
respiratori
howev
ct
exacerb
lung
patholog
influenza
viru
infect
induct
potent
proinflammatori
cytokin
coadministr
neutral
antibodi
ct
attenu
lung
patholog
increas
protect
influenza
viru
therefor
hypothes
intranas
applic
mucos
stimul
induc
antivir
cytokin
except
may
effect
influenza
viru
infect
regard
polyethyleneimin
pei
mucos
adjuv
exhibit
stronger
mucos
adjuvant
induc
much
lower
express
cholera
toxin
subunit
b
ctb
therefor
first
time
test
pei
potenti
protect
effect
influenza
viru
infect
tenweekold
specificpathogenfre
spf
femal
balbc
mice
anesthet
pelltobarbitalum
natricum
pb
contain
kd
linear
pei
polysci
warrington
pa
ctb
sigmaaldrich
st
loui
mo
usa
pb
alon
control
intranas
administ
twice
h
challeng
influenza
viru
mous
bodi
weight
monitor
everi
day
greater
loss
initi
bodi
weight
euthan
shown
figur
bodi
weight
mice
peipretr
group
remain
stabl
day
day
challeng
gradual
decreas
day
total
loss
recov
contrast
bodi
weight
mice
ctb
pbspretreat
group
decreas
significantli
begin
day
reach
loss
day
respect
challeng
final
surviv
rate
mice
peipretr
group
wherea
mice
ctb
pbspretreat
group
figur
examin
viral
titer
mous
lung
previous
found
pei
significantli
reduc
lung
viral
titer
day
challeng
wherea
viral
titer
lung
mice
ctb
pbspretreat
group
show
signific
differ
figur
subsequ
examin
lung
section
stain
hematoxylin
eosin
previous
day
infect
pulmonari
alveoli
rel
intact
inflammatori
cell
observ
lung
tissu
mice
peipretr
group
howev
lung
mice
ctb
pbspretreat
group
fill
abund
inflammatori
cell
figur
result
suggest
intranas
applic
pei
efficaci
protect
mice
challeng
influenza
viru
determin
efficaci
pei
anoth
subtyp
influenza
viru
pretreat
mice
pb
contain
pei
pb
alon
challeng
influenza
viru
mice
peipretr
group
fulli
protect
challeng
show
signific
bodi
weight
loss
figur
surviv
rate
wherea
pb
group
lost
bodi
weight
show
surviv
rate
day
postchalleng
figur
therefor
peimedi
protect
influenza
viru
infect
subtypespecif
elucid
mechan
action
pei
examin
rna
level
gmcsf
lung
mice
pretreat
pei
ctb
pb
respect
viral
challeng
use
quantit
revers
transcriptionpcr
qrtpcr
previous
report
cytokin
interferon
gmcsf
effect
protect
influenza
shown
supplementari
figur
pei
induc
significantli
higher
rna
level
ctb
pb
furthermor
rna
level
gmcsf
elicit
pei
similar
induc
ctb
much
higher
induc
pb
rna
level
mice
pretreat
ctb
adjuv
approxim
higher
mice
pretreat
pei
pb
respect
result
suggest
gmcsf
good
cytokin
act
protect
mediat
influenza
viru
infect
wherea
bad
cytokin
exacerb
patholog
primarili
lung
influenza
infect
summari
demonstr
pei
mucos
stimul
topic
intranas
administr
highli
effect
prevent
influenza
viru
infect
compar
bacteriaproduc
toxin
ctb
chemic
synthes
polym
pei
safer
mucos
applic
human
pei
test
sever
clinic
trial
gene
deliveri
vivo
demonstr
good
safeti
moreov
low
cost
product
abund
make
pei
suitabl
urgent
widespread
use
time
influenza
epidem
pandem
